Summary

CHARISMA (Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management, and Avoidance) is the first clinical trial to evaluate long-term effectiveness of clopidogrel plus aspirin in a population of high-risk patients, including symptomatic individuals with documented disease. Principal investigator Deepak Bhatt, MD, of the Cleveland Clinic Cardiovascular Coordinating Center, presented results from more than 15,000 study participants followed for a median of 2.3 years.